Fidelity Investments’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Fidelity Investments’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	–	–	5679
2022 Q3	$0	Hold	1	–	–	﹤0.01%	5594
2022 Q2	$0	Hold	1	–	–	﹤0.01%	5697
2022 Q1	$0	Buy	+1	New	+$17	﹤0.01%	5681
2021 Q3	–	Hold	0	–	–	–	5285
2021 Q2	–	Hold	0	–	–	–	5116

Other funds holding TMBR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

CPG

Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Fidelity Investments's TMBR Position: Q4 2022 in Review

Fidelity Investments sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2022, closing a stake of 1 share.

Fidelity Investments first reported a position in TMBR in Q1 2022 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 11 funds tracked by Wall St. Rank hold TMBR as of Q4 2022.

Fidelity Investments reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Fidelity Investments sold 1 Timber Pharmaceuticals, Inc. share in Q4 2022.
Fidelity Investments first reported a position in Timber Pharmaceuticals, Inc. in Q1 2022 and held it in 3 quarters.
Fidelity Investments's Timber Pharmaceuticals, Inc. position peaked at $0 in Q3 2022.
11 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2022.

Based on Fidelity Investments's 13F filing for Q4 2022, filed 13 Feb 2023.